Portfolio

To address AMR and protect the lives of people around the world, PACE is providing funding and support for a portfolio of early-stage projects to help grow the pipeline of high-quality antimicrobial therapeutics and associated diagnostics.

Supporting the best innovations to address the global threat of AMR

We are supporting a diverse portfolio of projects aimed at developing new tests and treatments for bacterial infections with high unmet need. Through a series of funding rounds available to academics and SMEs worldwide, we are selecting, investing in and supporting the most promising projects. We are offering a collaborative approach to project development through access to advisors, mentors, potential project partners and enabling technologies and capabilities. By supporting the projects in this way, we are helping to give them the best chance of success and position them for onward funding, investment and development. More projects will enter the portfolio as the programme progresses. This page highlights the innovators and projects that are currently in the PACE portfolio.

Portfolio Projects


Filters
Active Closed Diagnostic Therapeutic

Clear filters

InnotiveDx

Project title: InnotiveDx novel UTI diagnostic system prototype optimisation and first clinical use 


Justus Liebig University Giessen (JLU) and Infex Therapeutics

Project title: Novel drugs against Gram-negative bacterial pathogens


Kinvard Bio

Project title: Development of oxepanoprolinamides for the treatment of Gram-negative bacterial infections 


McMaster University

Project title: Lariocidins: direct-acting, non-traditional broad-spectrum lasso peptide antibacterials with a novel mechanism of action 


Obulytix

Project title: Precision Lysin Therapeutics (PLTs) for polymicrobial Gram-negative HABP/VABP and associated bacteremias 


Oxford Drug Design

Project title: Leucyl-tRNA synthetase inhibitor for oral therapy of urinary tract infections


PhalconBio

Project title: Engineered Phage Therapeutics (EPTs) to treat P. aeruginosa infections in bronchiectasis patients


ProtonDx

Project title: Rapid and portable molecular diagnostic for urinary tract infections to combat antimicrobial resistance in primary and secondary care settings


Triari Pharmaceuticals

Project title: Lead optimisation of mAbs targeting Acinetobacter baumannii iron acquisition proteins.